We would love to hear your thoughts about our site and services, please take our survey here.
Conservative revenue growth of near on 100% is pretty damn good in the current market conditions. We'll done Gerry and all the team. A fantastic achievement.
Great news. Another substantial contract win.
Dollar Shave Club appears to be a fairly standard online retailer which recommends products according to your grooming needs and preferences. There is no IP value as there is with STC, no database of microbiome data beneficial to both the cosmetic and medical industries, and not the plethora of possible revenue streams as with STC. STC is a unique business model as no other company in the world has such a massive and growing skin microbiome data set. Hence it would seem that any valuation for STC could justifiably be at a substantially larger sales multiple compared to Dollar Shave Club.
It is of course very difficult to value STC at present so it would be unwise to speculate. However Gerry has suggested on numerous occasions that it has unicorn potential. With that in mind and given its current exponential growth I would be very surprised if STC were to be sold that he would give it away for mate's rates. In my opinion Gerry will wish to hang on to it and see it grow as part of a JV to its full potential.
Yes it appears to be another ctDNA which although it could be used as a prescreening tool would not replace the very important need for repeat biopsies of intact cancer cells, which of course Parsortix would provide. Angle's strategy is not to compete with other liquid biopsy systems but to work alongside them offering additional information, benefiting both sides.
CtDNA liquid biopsy testing has been around for quite some time now but it is a limited analyte. AGL is addressing those markets which ctDNA can not address which will significantly raise its profile and status as a superior liquid biopsy system. The dozens of peer reviewed publications AGL has under its belt already have already placed AGL firmly on the map, but its profile will be substantially raised by the commercial deals unfolding over the coming months. There is massive upside potential as AGL's IP and commercial value is gradually established.
It's a shame that the chat board has degenerated to pantomime status when there is so much to look forward to. I remember the time, actually prior to FDA approval when posters were more mature and informed, but that appears to have fallen by the wayside.
For those who still have a genuine modicum of interest in AGL here is something to be excited about:
1. Ovarian clinical study verification results due anytime now.
2. Solaris Health prostate cancer clinical studies to commence Q3.
3. Further contracts secured with pharma services companies.
4. Lab accreditation in the US and UK possibly later this year.
Patience is all that's needed. Listen to the AGM presentation to get an idea as to the market potential. Companies with such ground breaking technologies which can revolutionise cancer treatment whilst providing fantastic returns for shareholders of the long-term don't appear everyday.
This is phenomenal news and opens up so many possibilities for future expansion. Really exciting times ahead and well done to Gerry and the team for having got this far. Looking forward to hearing more at the AGM.
Check out the STC twitter. Something involving ITN. Sounds promising
Fantastic news. Nice one Gerry!
Thompi, you may well be right but there is always the risk that traders will get on board as opposed to investors. Ultimately the long-term story is what is important. I can understand the frustration of those who bought at 150p but I still feel if you hold for the medium term you will be well rewarded.
Fever, your negativity towards Angle I feel is unwarranted considering what Angle has achieved under AN's leadership.
Gaining an FDA approval was a phenomenal achievement. Other companies in the space haven't even applied to the FDA because they've realised how difficult it is to obtain. It is testament to Newland's dogged determination and persistence and thanks to a great team that approval was finally granted, after 6 years of relentless hard work and constant dialogue with the FDA. As far as commercialisation is concerned Angle were always constrained in obtaining contracts prior to FDA approval, however now it has happened we're beginning to see real traction. Listen to the AGM presentation for a detailed explanation of the route to commercialisation. It was fairly inevitable that a placing would have to happen to tie the company over for a while until meaningful revenues kick in. Revenues will be modest to start with but I see an exponential explosion of revenue within two to three years. Angle is probably one of the safest stocks on AIM, with its ground-breaking technology which will revolutionise cancer treatment. Enormous barrier to entry, literally years away for any competitor in a $100 billion market. If 2-3 years is too long for some shareholders they should move on now. As AN explained he is looking for long-term investors, not jam tomorrow traders. This is definitely one to hold for the long term. And what better company if purely from an ethical and medical standpoint!
Noelpro, I'm as confused about the whole thing as you are. As far as I'm aware Poolbeg's data is the same as Open Orphans's, which Hvivo has accumulated over the years, but I may be wrong. Poolbeg as you say are at least using the data to design new drugs using AI, but why Orph aren't monetising the data using the DIM model I don't understand. It seems like a missed opportunity to me. I understand the economic conditions aren't right for spin-offs at the moment but surely DIM could be put into a subsidiary company of Orph to kick-start the monetising. I really don't know what Cathal is doing these days since Mo took over.
I hope on the the day of the announcement of any Leap sale or IPO that shares in Seed are suspended and then any proceeds from the Leap sale dividended back to shareholders. It seems a fairer way of rewarding long-term shareholders and would avoid the inevitable massive spike on the day of announcement, which would result in the 'winner who sells first takes all' result you always get with 'pop and drop' stocks.
Great video Trills from a marketing point of view. This video needs to get out there. Anyone viewing it should share it on their chosen social media platforms. This could go viral.